Editas Medicine (EDIT) Depreciation & Amortization (CF) (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $721000.0 in Q3 2025.

• Depreciation & Amortization (CF) for Q3 2025 came in at $721000.0, down 54.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 million (down 23.02% YoY), and the FY2024 annual result was $5.8 million, down 4.77% from the prior year.
• Depreciation & Amortization (CF) retreated to $721000.0 in Q3 2025 per EDIT's latest filing, from $1.8 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q1 2025 and troughed at $721000.0 in Q3 2025.
• A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2021 and 2025: Depreciation & Amortization (CF) jumped 45.74% in 2021, then plunged 54.91% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.6 million in 2021, then increased by 1.22% to $1.6 million in 2022, then fell by 4.76% to $1.5 million in 2023, then declined by 8.06% to $1.4 million in 2024, then plunged by 47.79% to $721000.0 in 2025.
• Business Quant data shows EDIT's Depreciation & Amortization (CF) at $721000.0 in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q1 2025.